FibroGen Inc (NASDAQ:FGEN) announced topline data from the Phase 3 LELANTOS-1 trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids.
The study did not meet the primary endpoint of the Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased